Sign Out
Idarubicin hydrochloride is a potent myelosuppressant and combination chemotherapy regimens that contain other agents with similar action may lead to additive toxicity, especially with regard to bone marrow/hematologic and gastrointestinal effects (see Precautions). The use of idarubicin hydrochloride in combination chemotherapy with other potentially cardiotoxic drugs, as well as the concomitant use of other cardioactive compounds (e.g., calcium channel blockers), requires monitoring of cardiac function throughout treatment.
Changes in hepatic or renal function induced by concomitant therapies may affect idarubicin hydrochloride metabolism, pharmacokinetics, and therapeutic efficacy and/or toxicity (see Precautions).
An additive myelosuppressant effect may occur when radiotherapy is given concomitantly or within 2-3 weeks prior to treatment with idarubicin hydrochloride.
